. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the […]
continue readingKuros Biosciences Reports Results for First Half 2021
. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 million in H1 2020 Net operating costs of CHF 8.6 million, increase led by higher […]
continue readingKuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license […]
continue readingKuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of […]
continue readingKuros Biosciences to present at upcoming U.S. spine conferences
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical data for MagnetOs bone graft at the upcoming 16th annual meeting of the Korean American […]
continue readingKuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations
MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor […]
continue readingKuros to receive $4 million milestone payment from Checkmate Pharmaceuticals
. • Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in patients with anti-PD-1 refractory advanced melanoma • Kuros stands to receive up to $49 million additional milestones plus royalties on sales Kuros Biosciences (“Kuros”), a leader in next generation bone graft technologies, today announced it will receive a […]
continue readingKuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion
Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’. This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH. This patent strengthens […]
continue readingKuros Biosciences publishes invitation to the Annual General Meeting 2021
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today published the invitation and agenda for its Annual General Meeting, to be held on April 19, 2021, 11.00 a.m. The Annual General Meeting will be held under conditions of the Federal Council’s […]
continue readingKuros Biosciences reports results for the full year 2020
Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spine Commercial rollout in the U.S. and Europe on track Distribution agreements for The Netherlands, Austria, and Switzerland for MagnetOs […]
continue reading